ImmuPharma (LON:IMM) Trading Up 14.3% – Still a Buy?

ImmuPharma plc (LON:IMM)’s share price was up 14.3% during trading on Thursday . The stock traded as high as GBX 13.95 ($0.19) and last traded at GBX 12.46 ($0.17). Approximately 2,830,881 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 8,358,668 shares. The stock had previously closed at GBX 10.90 ($0.15).

ImmuPharma Stock Up 11.5%

The company has a market capitalization of £61.08 million, a price-to-earnings ratio of -13.65 and a beta of 1.53. The company has a 50 day simple moving average of GBX 8.52 and a 200 day simple moving average of GBX 4.55.

ImmuPharma (LON:IMM) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.